Clinical trials in Potsdam – page 24

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Potsdam at a glance

1 819

clinical trials

Research sites1

Quick filters

1 819 trials in Potsdam

Open in trial search

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cladribine
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Ellipses Pharma Limited

Contact Research Centre

Major depression

Recruiting

A Study of SPT-300 Compared to Placebo for Adults with Major Depressive Disorder with or without Anxious Distress

Investigational

A Study of SPT-300 Compared to Placebo for Adults with Major Depressive Disorder with or without Anxious Distress

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Brexanolone caprilcerbate
Sponsor:Seaport Therapeutics Inc.

Contact Research Centre

Myasthenia gravis

Recruiting

A Study Comparing Nipocalimab and Efgartigimod for Adults with Generalized Myasthenia Gravis

Registered drugNo placebo

A Study Comparing Nipocalimab and Efgartigimod for Adults with Generalized Myasthenia Gravis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Janssen Cilag International

Contact Research Centre

Arteriosclerosis

Recruiting

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Olpasiran
Sponsor:Amgen Inc.

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Universita Degli Studi Di Milano Bicocca

Contact Research Centre

Hepatocellular carcinoma

Recruiting

A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

Registered drug

A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Lenvatinib
Sponsor:CatalYm GmbH

Contact Research Centre

Parkinson's disease

Recruiting

A Study Testing the Safety of IRL757 in Adults with Parkinson's Disease Who Have Apathy

Investigational

A Study Testing the Safety of IRL757 in Adults with Parkinson's Disease Who Have Apathy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:IRL757
Sponsor:Integrative Research Laboratories Sweden AB

Contact Research Centre

Porphyria non-acute

Recruiting

Long-term study of bitopertin safety and effectiveness in patients with erythropoietic protoporphyria or X-linked protoporphyria

InvestigationalNo placebo

Long-term study of bitopertin safety and effectiveness in patients with erythropoietic protoporphyria or X-linked protoporphyria

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bitopertin
Sponsor:Disc Medicine Inc.

Contact Research Centre

Squamous cell carcinoma of skin

Recruiting

A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

InvestigationalNo placebo

A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Onfekafusp Alfa
Sponsor:Philogen S.p.A.

Contact Research Centre

Basal cell carcinoma

Recruiting

Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

InvestigationalNo placebo

Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Onfekafusp Alfa
Sponsor:Philogen S.p.A.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

Early-stage breast cancer interventions
HPV-positive oropharyngeal cancer treatments
Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

Actinic keratosis treatments
Hidradenitis suppurativa therapy
Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

Relapsing-remitting MS treatments
Novel therapeutic approaches
Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

Lipoprotein management
Cholesterol reduction therapies
Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Back to Germany All countries